Baylor College of Medicine

Texas Children's Hospital

Texas Children's Hospital
6701 Fannin, Suite 1020
Houston, TX 77030
United States
Call 832-822-3380 Email this location

Baylor College of Medicine/Texas Children’s Hospital (Baylor/TCH) is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Dr. Maria J. Redondo, the TrialNet team at Baylor/TCH is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators 
Maria J. Redondo, MD, PhD, MPH, is Associate Professor of Pediatrics in the Diabetes and Endocrinology Section at the Texas Children's Hospital and Baylor College of Medicine, which she joined in 2010. She trained and practiced as a pediatric endocrinologist at the Barbara Davis Center between 1997 and 2004 for Childhood Diabetes, where she developed her clinical and research interest in Type 1 Diabetes. Her research goal is to find the way to prevent the progression of Type 1 Diabetes.
Research Coordinators 
"Type 1 Diabetes is very hard for families to deal with. I am very proud to be in the best research team to find a prevention for future generations so they will not suffer from this disease anymore." Xiati Zheng, RN, BSN

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with Baylor College of Medicine to offer convenient participation in our research programs
El Paso

El Paso Diabetes Association
2101 N.Oregon Street, El Paso, TX 79902

San Antonio

Children's Hospital of San Antonio
333 North Santa Rosa, San Antonio, TX 78207

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study


TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.


Teplizumab (Closed to Enrollment-Study Ongoing)

We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.